NAVELBINE^®

 Navelbine^® i.v. (Vinorelbine) is a semi-synthetic derivative of a vinca alkaloid and a well-studied and long utilized therapy for the treatment of non-small cell lung cancer (NSCLC).

With more than 1 million patients treated throughout the world since its first launch, Navelbine^® is one of the most prescribed anti-cancer products in Europe. Navelbine^® is currently registered in 80 countries. 

Registration in USA
Navelbine^®10 mg/1mL Single-Use Vial: NDC 64370-532-01
Navelbine^®50 mg/5mL Single-Use Vial: NDC 64370-532-02

Navelbine^® Key dates in US:

1978 - Vinorelbine is discovered and patented by CNRS (National Center for Scientific Research).

1982 - Pierre Fabre initiates the development of intravenous Vinorelbine.

1988 - Navelbine^® is licensed by Pierre Fabre to Burroughs Wellcome for the US and Canada.

1989 - Navelbine^® is first approved for NSCLC treatment (France).

1994 - Navelbine^® is approved for use in the USA (Indicated for NSCLC).

1995 - Navelbine^® is launch by Burroughs Wellcome in the USA. Burroughs Wellcome becomes Glaxo Wellcome and later GlaxoSmithKline.

Dec. 19th 2005 - Pierre Fabre Pharmaceuticals Inc. takes over the marketing of Navelbine^® in the USA on an exclusive basis.


Pierre Fabre is the historical and exclusive manufacturer of all Navelbine^® distributed in the USA.